Newark-based Foresee Pharmaceuticals Sets Its Sights on China
Partnership with GenScience Pharmaceuticals Brings Cutting-edge Technology to Asian Market
Most would agree that Foresee Pharmaceuticals’ innovators possess foresight. The core product is a proprietary drug-delivery technology that controls a medication’s release over an extended period — from a few weeks to up to six months.
However, the clinical-stage pharma company’s name was inspired by the technology’s advantages: comfort, compliance, convenience and cure. In other words, four Cs.
Consider the company’s novel FP-001 program — Camcevi — a leuprolide mesylate injectable suspension (LMIS) for prostate cancer. Since patients need fewer injections, they’re more likely to be comfortable and compliant, says Dr. Yuhua Li, co-founder and vice president of research and development at Foresee. The treatment is more convenient, and it can lead to a better treatment outcome.